(CIDRAP News) – The US government today announced the award of a $231 million, 5-year contract to an Australian company for advanced development of a single-dose, long-acting influenza drug in the neuraminidase inhibitor class.
The contract was awarded to Biota Scientific Management Pty, Ltd., of Melbourne, according to the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services.